Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
about
Treatment and Outcome Analysis of 205 Patients with Multidrug-resistant TuberculosisReminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatmentReminder systems and late patient tracers in the diagnosis and management of tuberculosisImipenem for treatment of tuberculosis in mice and humansImpact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysisPurification of a novel coenzyme F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatisIn vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugsMoxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosisWhich aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice?Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the PhilippinesTreatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysisPrimary drug-resistant tuberculosis in Hanoi, Viet Nam: present status and risk factorsThe effect of early versus late treatment initiation after diagnosis on the outcomes of patients treated for multidrug-resistant tuberculosis: a systematic reviewThe Effectiveness and Safety of Fluoroquinolone-Containing Regimen as a First-Line Treatment for Drug-Sensitive Pulmonary Tuberculosis: A Systematic Review and Meta-AnalysisIsoniazid-resistant cavitary tuberculosis in a physician following isoniazid prophylaxis.Use of molecular techniques to distinguish between treatment failure and exogenous reinfection with Mycobacterium tuberculosis.Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings.AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals.Six-month therapy with aerosolized interferon-gamma for refractory multidrug-resistant pulmonary tuberculosis.Comparison of Xpert MTB/RIF with line probe assay for detection of rifampin-monoresistant Mycobacterium tuberculosis.Molecular analysis of the gene encoding F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis.Does directly observed therapy (DOT) reduce drug resistant tuberculosis?Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus".Efficacy and Safety of Mycobacterium indicus pranii as an adjunct therapy in Category II pulmonary tuberculosis in a randomized trialMortality and associated risk factors in a cohort of tuberculosis patients treated under DOTS programme in Addis Ababa, Ethiopia.Mutations in the rpoB gene of rifampin-resistant Mycobacterium tuberculosis strains isolated mostly in Asian countries and their rapid detection by line probe assayBacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia.Molecular characterization of rifampin-resistant isolates of Mycobacterium tuberculosis from Hungary by DNA sequencing and the line probe assay.Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons.Management of tuberculosis. Choosing an effective regimen and ensuring compliance.Molecular detection of fluoroquinolone-resistance in multi-drug resistant tuberculosis in Cambodia suggests low association with XDR phenotypes.Issues facing TB control (7). Multiple drug-resistant tuberculosis.Ancillary-care responsibilities in observational research: two cases, two issuesEvaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.Outcomes of multidrug-resistant tuberculosis among binational cases in El Paso, Texas.Medicaid policies for HIV-related prescription drugs.The need for epidemic intelligenceEffectiveness and cost of rapid and conventional laboratory methods for Mycobacterium tuberculosis screeningTreatment outcome and mortality among patients with multidrug-resistant tuberculosis in tuberculosis hospitals of the public sectorMultidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai.
P2860
Q21563671-5D320BE6-1FBA-4828-B191-BFC82400C93DQ24187942-1547F8DC-1716-4BC8-BE43-3B11822BFB38Q24241007-650DEA00-EB5A-4253-843D-8F0576BF263CQ24531943-76D55969-2A6F-4466-8AFB-8885D4D4FCD7Q24554274-80D738D2-08E6-4A5C-BA98-1964F94962F8Q24683754-0EB9F8C7-D60D-48E6-B11D-1B825DC6154AQ28344608-F54067B0-7C59-4509-BDAC-B7BAC3B9A4D8Q28369466-2C33E167-52B4-4EC7-B31B-D99DC4733CCEQ28379500-573B369E-6742-4451-9D77-1E3204070864Q28469046-4C78A6D4-EB35-460B-B683-8C52B2156329Q28476110-D331E8CA-9E27-41B4-9485-9A6CDBEEFB7FQ28535281-47F6E7DE-DF96-4698-8779-54C4F1625757Q28551772-E76CA5A9-E72D-4451-9A95-B450E6A663ACQ28553119-4EA9780E-25F4-4FB6-8663-5A4C4CD2B8D2Q30310172-68C6520E-BBC7-4837-9DD5-551A0CBD9FF2Q31089497-3CD0EDA3-BC50-4746-A970-C0811E7152E2Q31119394-18EFCC03-584E-45D8-A3BD-B4D13DDBBF74Q33604838-B9CE31A2-90BC-4AC2-9877-8CB5A7291528Q33654669-210847C5-24D6-41AA-8C1D-4886D8DDBFF8Q33703611-3201FED2-0B1B-4159-9116-FE368D22A55DQ33729195-A5424119-3488-46D9-938A-96F77E84C225Q33788435-4EB48DC2-B68D-4C5E-918A-2F0F1DCA39A6Q33791822-CBCD8956-4504-4B81-BDF0-35589315FF54Q33793948-3D711061-0420-4279-B400-43C70B1533EAQ33901443-1FA43531-87B4-47FA-ABAE-08D164C2B320Q33962106-9AA783FA-09BA-4158-9C76-C1DECB460821Q33964071-6EE37981-45E0-489B-9B4F-5F2064F7EDBAQ33973746-5CFD12BC-BCB9-4AB8-BC6D-073B6DEB13B9Q33974090-7BF7C665-8925-4962-B432-9534E608AFD6Q34010263-B92C2F1B-9D3B-4AC8-915C-6134BEAE633FQ34034062-A2FCB453-9D7D-4A16-8584-60FC409F142FQ34113946-56FF5C2B-25AA-458C-9190-96929B0DBF36Q34154566-C7793533-91CA-4B4C-9871-2170F0E8470FQ34184543-86242878-293B-429A-BFC9-F009B20D36FFQ34240055-7A072EF0-925D-4055-BB67-F851C029F845Q34321740-13438650-2E2C-4A6C-9F0E-F819428767E5Q34404453-122D81F6-0D6D-455C-B71C-634767AE9843Q34405474-14690025-F853-4C51-8445-9E35B2753C62Q34451895-FCF5885D-222C-437B-94C9-08303BBFB333Q34453089-2D98C864-667C-46AD-8964-0AD0BECF3818
P2860
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
description
1993 nî lūn-bûn
@nan
1993 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@ast
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@en
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@nl
type
label
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@ast
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@en
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@nl
prefLabel
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@ast
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@en
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@nl
P2093
P3181
P1476
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin
@en
P2093
P304
P3181
P356
10.1056/NEJM199302253280802
P407
P50
P577
1993-02-01T00:00:00Z